Key Takeaway
Explore what we know about retatrutide's upcoming brand name, how pharmaceutical naming works, and why Eli Lilly may use multiple names for different indications.
Eli Lilly hasn't yet announced the commercial brand name for retatrutide. The company typically reveals brand names closer to FDA approval, usually after submitting the New Drug Application and receiving a Proprietary Name Review from the FDA's Division of Medication Error Prevention and Analysis. Until that process is complete, the medication is known only by its generic name, retatrutide, and its development code, LY3437943.
How Pharmaceutical Brand Names Are Chosen
The process of naming a medication is far more complex than most people realize. It involves branding strategy, regulatory approval, trademark law, and patient safety considerations. A name that sounds appealing to marketers might be rejected by the FDA because it looks or sounds too similar to an existing drug name, creating a risk of dispensing errors.
Pharmaceutical companies typically begin the naming process one to two years before anticipated approval. They hire specialized naming agencies that generate hundreds or even thousands of candidate names. These candidates are evaluated through multiple filters: linguistic analysis in dozens of languages to avoid unintended meanings, handwriting legibility tests (can a pharmacist misread the name?), phonetic similarity screening against thousands of existing drug names, and trademark searches to ensure the name isn't already owned by another entity.
The surviving candidates are submitted to the FDA, which conducts its own independent review. The FDA rejects a significant percentage of proposed names, sometimes multiple times, sending companies back to generate new options. The entire process can take 12 to 18 months from initial submission to final approval of the name.
Lilly's Naming Pattern: A Two-Name Strategy
Eli Lilly's approach with tirzepatide offers the clearest precedent for what to expect with retatrutide. Tirzepatide was approved under two different brand names for two different indications: Mounjaro for type 2 diabetes (approved June 2022) and Zepbound for chronic weight management (approved November 2023). Same molecule, different names, different marketing, different patient populations.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
This two-name strategy serves several purposes. It allows Lilly to market the medication differently to diabetes patients and weight management patients, who have different concerns, motivations, and healthcare experiences. It creates separate revenue streams that can be tracked independently. And it can help with insurance coverage, as payers may have different formulary positions for diabetes medications versus obesity medications.
Novo Nordisk used the same approach with semaglutide: Ozempic for diabetes and Wegovy for weight loss. This has become the industry standard for GLP-1 class medications that have dual indications.
Retatrutide is being studied for at least three indications: obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH). It's plausible that Lilly could launch retatrutide under two or even three different brand names, each tied to a specific indication and marketing strategy.
What the Name Might Sound Like
While we can't predict the exact brand name, pharmaceutical naming trends and Lilly's own history offer some clues about the general direction.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Modern drug brand names tend to be short (two to three syllables), distinctive, and easy to pronounce across English-speaking markets. They often incorporate sounds that convey attributes associated with the drug's benefits. Hard consonants like K, Z, and X suggest strength and efficacy. Smooth vowel sounds suggest ease and comfort. Names ending in vowels or soft consonants tend to feel more approachable.
Lilly's recent brand names follow recognizable patterns. Mounjaro evokes strength and aspiration (Mount Kilimanjaro). Zepbound suggests momentum and energy. Jardiance (empagliflozin, a diabetes medication) conveys a sense of living well. Verzenio (a cancer drug) sounds clinical and precise. The company tends to choose names that are distinctive and memorable without being overly clinical.
For retatrutide's obesity indication, expect a name that conveys transformation, progress, or vitality. For the diabetes indication, the name may emphasize control, balance, or health. These are educated guesses based on industry patterns rather than any inside knowledge.
The Generic Name: Retatrutide
While the brand name remains unknown, the generic name "retatrutide" is already established and won't change. Generic names (also called International Nonproprietary Names or INNs) follow strict conventions set by the United States Adopted Names (USAN) Council and the World Health Organization.
The "-tide" suffix identifies retatrutide as a peptide-based medication. The "-trutide" ending specifically designates it as a GLP-1/GIP/glucagon triple receptor agonist. This suffix system helps healthcare professionals quickly identify a drug's class. For comparison, semaglutide's "-glutide" suffix identifies it as a GLP-1 receptor agonist, and tirzepatide's "-zepatide" suffix identifies it as a dual GLP-1/GIP agonist.
The "reta-" prefix is the unique identifier that distinguishes retatrutide from other triple agonists in development. If other companies bring competing triple agonists to market, those molecules would also carry the "-trutide" suffix but with different prefixes.
Why the Name Matters for Patients
You might wonder why the brand name matters at all beyond marketing. In practice, brand names have real implications for patients in several ways.
Insurance and coverage. Different brand names for different indications allow insurers to make separate coverage decisions. A plan might cover the diabetes-indicated version but not the obesity-indicated version, or vice versa. Understanding which brand name corresponds to your indication helps you manage the coverage space.
Prescribing clarity. When your doctor writes a prescription, the brand name specifies not just the molecule but the approved indication and dosing regimen. Mounjaro and Zepbound contain compounded formulations of the active ingredient but are prescribed at different doses and for different purposes. The same will likely be true for retatrutide's various brand names.
Public perception and stigma. Separate brand names for diabetes and weight loss help reduce the stigma some patients feel about taking an "obesity drug." A patient prescribed the diabetes-indicated brand may feel more comfortable than one prescribed a medication overtly marketed for weight loss, even though the active ingredient is in the same class. Whether this is rational is debatable, but it reflects real patient psychology.
Supply and availability. Different brand names can have different supply chains and availability. During the tirzepatide shortage period, Mounjaro and Zepbound had different availability at different times, and patients sometimes found one easier to obtain than the other. Separate brand names allow Lilly to prioritize manufacturing and allocation by indication if needed.
Keeping Track of Retatrutide Before the Brand Name
Until the brand name is announced, here are the identifiers you can use to follow retatrutide's progress. The generic name "retatrutide" is the most commonly used in medical literature and news coverage. The development code "LY3437943" appears in clinical trial registrations on ClinicalTrials.gov and in early research publications. Some media outlets informally refer to it as "Lilly's triple agonist" or "the triple G," though these aren't official designations.
When searching for information, using "retatrutide" will yield the most thorough results. As the brand name announcement approaches, typically three to six months before anticipated FDA approval, pharmaceutical news outlets and Lilly's investor communications will be the first sources to report it.
Timeline Expectations
Based on Lilly's Phase 3 trial timelines and the typical regulatory process, a brand name announcement for retatrutide could come as early as late 2026, though 2027 is also plausible depending on how the Phase 3 data reads out and how quickly Lilly submits its NDA. The FDA typically takes 10 to 12 months to review a standard NDA, or 6 months under priority review, which retatrutide may qualify for given the strength of its efficacy data.
When the name is announced, we will update this page. In the meantime, "retatrutide" is the name to know, and the data behind the molecule matters far more than whatever branding Lilly ultimately chooses to put on the box.